JP2019503176A - 処置に対する応答を予測するための方法 - Google Patents

処置に対する応答を予測するための方法 Download PDF

Info

Publication number
JP2019503176A
JP2019503176A JP2018536437A JP2018536437A JP2019503176A JP 2019503176 A JP2019503176 A JP 2019503176A JP 2018536437 A JP2018536437 A JP 2018536437A JP 2018536437 A JP2018536437 A JP 2018536437A JP 2019503176 A JP2019503176 A JP 2019503176A
Authority
JP
Japan
Prior art keywords
composite
human subject
il1b
gene pattern
polymorphic locus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018536437A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019503176A5 (https=
Inventor
リン ドーセット−シュタム
リン ドーセット−シュタム
ゴードン ダブリュ． ダフ
ゴードン ダブリュ． ダフ
ケニス エス． コーンマン
ケニス エス． コーンマン
Original Assignee
インターロイキン ジェネティクス， インコーポレイテッド
インターロイキン ジェネティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インターロイキン ジェネティクス， インコーポレイテッド, インターロイキン ジェネティクス， インコーポレイテッド filed Critical インターロイキン ジェネティクス， インコーポレイテッド
Publication of JP2019503176A publication Critical patent/JP2019503176A/ja
Publication of JP2019503176A5 publication Critical patent/JP2019503176A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
JP2018536437A 2016-01-12 2017-01-12 処置に対する応答を予測するための方法 Pending JP2019503176A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662277760P 2016-01-12 2016-01-12
US62/277,760 2016-01-12
PCT/US2017/013101 WO2017123696A1 (en) 2016-01-12 2017-01-12 Methods for predicting response to treatment

Publications (2)

Publication Number Publication Date
JP2019503176A true JP2019503176A (ja) 2019-02-07
JP2019503176A5 JP2019503176A5 (https=) 2020-02-20

Family

ID=57956384

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018536437A Pending JP2019503176A (ja) 2016-01-12 2017-01-12 処置に対する応答を予測するための方法

Country Status (6)

Country Link
US (2) US10894985B2 (https=)
EP (1) EP3402900A1 (https=)
JP (1) JP2019503176A (https=)
AU (1) AU2017207341A1 (https=)
CA (1) CA3011363A1 (https=)
WO (1) WO2017123696A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506225A (ja) * 2017-01-12 2020-02-27 カーディオフォーキャスト リミテッド 心血管疾患を処置するための方法およびキット
JP2020178536A (ja) * 2019-04-23 2020-11-05 ジェネシスヘルスケア株式会社 アレルギー性結膜炎のリスクを判定する方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3011363A1 (en) 2016-01-12 2017-07-20 Interleukin Genetics, Inc. Methods for predicting response to treatment
DE102018104133B4 (de) * 2018-02-23 2025-02-20 Klinikum der Universität München, Anstalt des öffentlichen Rechts Biomarker zur Feststellung einer möglichen Unverträglichkeit gegenüber Metallimplantaten
US20210395751A1 (en) 2018-10-31 2021-12-23 The University Of Sydney Compositions and methods for treating viral infections
US20220249660A1 (en) * 2019-06-06 2022-08-11 Sitokine Limited Compositions and methods for treating lung, colorectal and breast cancer
WO2021028469A1 (en) * 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021205013A1 (en) * 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
US4988617A (en) 1988-03-25 1991-01-29 California Institute Of Technology Method of detecting a nucleotide change in nucleic acids
JP2897959B2 (ja) 1988-05-20 1999-05-31 エフ．ホフマン―ラ ロシュ アクチェンゲゼルシャフト 固定化された配列特異的プローブ
US4988167A (en) 1988-08-10 1991-01-29 Fergason James L Light blocking and vision restoration apparatus with glint control
US5118801A (en) 1988-09-30 1992-06-02 The Public Health Research Institute Nucleic acid process containing improved molecular switch
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5494810A (en) 1990-05-03 1996-02-27 Cornell Research Foundation, Inc. Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5270184A (en) 1991-11-19 1993-12-14 Becton, Dickinson And Company Nucleic acid target generation
ATE198358T1 (de) 1992-04-27 2001-01-15 Dartmouth College Detektion von gensequenzen in biologischen flüssigkeiten
CA2153387A1 (en) 1993-01-07 1994-07-21 Hubert Koester Dna sequencing by mass spectrometry
US5422252A (en) 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US6027923A (en) 1993-07-23 2000-02-22 Bio-Rad Laboratories, Inc. Linked linear amplification of nucleic acids
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
DE4331012A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5657255C1 (en) 1995-04-14 2002-06-11 Interleukin Genetics Inc Hierarchic biological modelling system and method
US5686246A (en) 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
EP2332958B1 (en) 1996-02-09 2016-04-20 Cornell Research Foundation, Inc. Detection of nucleic and sequence differences using the ligase detection reaction with addressable arrays
US5698399A (en) 1996-04-05 1997-12-16 Duff; Gordon W. Detecting genetic predisposition for osteoporosis
US6108635A (en) 1996-05-22 2000-08-22 Interleukin Genetics, Inc. Integrated disease information system
EP1736554B1 (en) 1996-05-29 2013-10-09 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US6117635A (en) 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US5866336A (en) 1996-07-16 1999-02-02 Oncor, Inc. Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
GB9618960D0 (en) 1996-09-11 1996-10-23 Medical Science Sys Inc Proteases
GB9621129D0 (en) 1996-10-10 1996-11-27 Duff Gordon W Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6720141B1 (en) 1999-11-01 2004-04-13 Interleukin Genetics, Inc. Diagnostics and therapeutics for restenosis
US6524795B1 (en) 1997-03-10 2003-02-25 Interleukin Genetics, Inc. Diagnostics for cardiovascular disorders
US6210877B1 (en) 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
US7820383B2 (en) 1997-03-10 2010-10-26 Interleukin Genetics, Inc. Method for diagnosing myocardial infarction
GB9711040D0 (en) 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
GB9723553D0 (en) 1997-11-07 1998-01-07 Duff Gordon W Prediction of the risk of chronic obstructive airway disease
US20050282198A1 (en) 1997-05-29 2005-12-22 Interleukin Genetics, Inc. Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype
US6437216B1 (en) 1997-11-13 2002-08-20 Interleukin Genetics Inc. Transgenic models of inflammatory disease
US6746839B1 (en) 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US20050032077A1 (en) 1998-03-10 2005-02-10 Duff Gordon W. Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6733967B1 (en) 1998-04-21 2004-05-11 Interleukin Genetics, Inc. Fetal testing for prediction of low birth weight
US6251598B1 (en) 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
IL144492A0 (en) 1999-02-10 2002-05-23 Interleukin Genetics Inc Therapeutics and diagnostics based on an il-1b mutation
US6506594B1 (en) 1999-03-19 2003-01-14 Cornell Res Foundation Inc Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
IL147182A0 (en) 1999-06-30 2002-08-14 Interleukin Genetics Inc Diagnostics and therapeutics for diseases associated with an il-1 inflammatory haplorype
EP1212464B1 (en) 1999-08-30 2006-02-22 Interleukin Genetics, Inc. Diagnostics and therapeutics for osteoporosis
US20100255475A1 (en) 1999-08-30 2010-10-07 Kornman Kenneth S Diagnostics and therapeutics for osteoporosis
US20090023147A1 (en) 1999-08-30 2009-01-22 Kenneth Kornman Diagnostics and therapeutics for osteoporosis
WO2002000933A2 (en) 2000-06-23 2002-01-03 Interleukin Genetics, Inc. Screening assays for identifying modulators of the inflammatory or immune responses
US20060183161A1 (en) 2000-07-17 2006-08-17 Martin Nicklin IL-ILI gene and polypeptide products
CA2434136A1 (en) 2001-01-08 2002-07-11 Interleukin Genetics, Inc. Mammalian tribbles signaling pathways and methods and reagents related thereto
WO2002101015A2 (en) 2001-06-11 2002-12-19 Interleukin Genetics, Inc. Integrative assays for monitoring molecular assembly events
AU2002320100A1 (en) 2001-06-15 2003-01-02 Interleukin Genetics, Inc. Methods for detecting and treating the early onset of aging-related conditions
US20080311581A1 (en) 2001-11-19 2008-12-18 David Wyllie Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
CN1753903B (zh) 2001-11-19 2010-05-12 白介素遗传公司 影响转录和对炎性和传染性疾病的敏感性的白细胞介素-1基因座的功能多态性
US20070264645A1 (en) 2002-01-25 2007-11-15 Kenneth Kornman IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
DE602004030367D1 (de) 2003-08-08 2011-01-13 Interleukin Genetics Inc Diagnostikum für osteoporose
US20080118920A1 (en) 2004-05-03 2008-05-22 Duff Gordon W Diagnostics And Therapeutics For Diseases Associated With An Il-1 Inflammatory Haplotype
US20060252050A1 (en) 2005-05-06 2006-11-09 Ordovas Jose M Genetic marker for weight regulation
US8105775B2 (en) 2005-10-25 2012-01-31 Interleukin Genetics, Inc. IL-1 gene cluster and associated inflammatory polymorphisms and haplotypes
CA2652041A1 (en) 2006-05-12 2007-11-22 Interleukin Genetics, Inc. Food compositions and methods of treating periodontal disease
US8101360B2 (en) 2006-11-15 2012-01-24 Interleukin Genetics, Inc. IL-1 gene cluster, insulin resistance and coronary artery disease associated polymorphisms and haplotypes and methods of using same
EP2217725A2 (en) 2007-11-08 2010-08-18 Interleukin Genetics, Inc. Diagnostics for aging-related dermatologic disorders
CA2723247A1 (en) 2008-05-02 2009-11-05 Interleukin Genetics, Inc. Detecting genetic predisposition to osteoarthritis associated conditions
JP5762282B2 (ja) 2008-05-02 2015-08-12 インタールーキン ジェネティクス， インコーポレイテッド 変形性関節症に関連する状態に対する遺伝的素因の検出
US20100136561A1 (en) 2008-05-16 2010-06-03 Interleukin Genetics, Inc. Genetic Markers for Weight Management and Methods of Use Thereof
BRPI0912727A8 (pt) 2008-05-16 2017-10-03 Interleulkin Genetics Inc Marcadores genéticos para controle de peso e métodos e uso dos mesmos
WO2010009377A2 (en) 2008-07-18 2010-01-21 Interleukin Genetics, Inc. Methods and compositions for pharmacogenetic analysis of anti-inflammatory drugs in the treatment of rheumatoid arthritis and other inflammatory diseases
US20100112570A1 (en) 2008-10-22 2010-05-06 Interleukin Genetics, Inc. Genetic Markers for Weight Management and Methods of Use Thereof
WO2011006070A2 (en) 2009-07-09 2011-01-13 Interleukin Genetics, Inc. Genetic association of polymorphisms in perilipin (plin) gene with resistance to weight loss
CN103547680B (zh) 2010-12-09 2017-05-24 白细胞介素遗传学公司 用于确定牙周病的严重性和进展的改进方法和试剂盒
BR112014007253A2 (pt) 2011-09-30 2017-03-28 Novartis Ag uso de anticorpos que se ligam a il-1beta
US20160002624A1 (en) 2012-05-17 2016-01-07 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
DK2991656T3 (da) 2013-05-01 2020-03-23 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
CA3011363A1 (en) 2016-01-12 2017-07-20 Interleukin Genetics, Inc. Methods for predicting response to treatment
US10329620B2 (en) 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AM. J. OPHTHALMOL., (2012), 154, [1], P.63-71, JPN6021005393, ISSN: 0004599766 *
HUM. GENET., (2008), 123, [4], P.387-398, JPN6021005390, ISSN: 0004599764 *
INVEST. OPHTHALMOL. VIS. SCI., (1999), 40, [12], P.3041-3046, JPN6021005394, ISSN: 0004599767 *
INVESTIG. OPHTHALMOL. VIS. SCI., (2012), 53, [14], ARVO ANNUAL MEETING ABSTRACT:ARTICLE.2040<URL:HTT, JPN6021005396, ISSN: 0004599768 *
システム/制御/情報, (2007), 51 [10], P.445-451, JPN6021005391, ISSN: 0004599765 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506225A (ja) * 2017-01-12 2020-02-27 カーディオフォーキャスト リミテッド 心血管疾患を処置するための方法およびキット
JP2020178536A (ja) * 2019-04-23 2020-11-05 ジェネシスヘルスケア株式会社 アレルギー性結膜炎のリスクを判定する方法
JP7108574B2 (ja) 2019-04-23 2022-07-28 ジェネシスヘルスケア株式会社 アレルギー性結膜炎のリスクを判定する方法

Also Published As

Publication number Publication date
AU2017207341A1 (en) 2018-08-02
EP3402900A1 (en) 2018-11-21
CA3011363A1 (en) 2017-07-20
WO2017123696A1 (en) 2017-07-20
US20210164052A1 (en) 2021-06-03
US10894985B2 (en) 2021-01-19
US20170198350A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
US20210164052A1 (en) Methods for predicting response to treatment
US11486006B2 (en) Methods and kits for treating cardiovascular disease
CN103333952B (zh) 年龄相关的黄斑变性中的遗传多态性
JP2019076095A (ja) 疾患危険因子を同定する方法
JP5676623B2 (ja) 加齢黄斑変性における遺伝的多型性
CA3202510A1 (en) Tl1a therapy compositions and methods of treatment therewith
WO2021205013A1 (en) Compositions and methods for treating covid-19
US20130244990A1 (en) Genetic polymorphisms associated with depression
US20220177982A1 (en) Methods Of Identifying Subjects Having An Increased Risk Of Developing A Coronavirus Infection And Treatment Thereof
US20210348235A1 (en) Genetic markers associated with response to crth2 receptor antagonists
US9670545B2 (en) Methods and kits for treating and classifying individuals at risk of or suffering from TRAP1 change-of-function
US20050255498A1 (en) APOC1 genetic markers associated with age of onset of Alzheimer&#39;s Disease
US20070289889A1 (en) Biomarkers For The Prediction Of Drug-In Duced Diarrhea
US20140045717A1 (en) Single Nucleotide Polymorphism Biomarkers for Diagnosing Autism
US20060177860A1 (en) Genetic markers in the HLA-DQBI gene associated with an adverse hematological response to drugs
US20060183146A1 (en) Genetic markers in the HLA-C gene associated with an adverse hematological response to drugs
US12514832B2 (en) Methods for using low-dose colchicine after myocardial infarction
US8216787B2 (en) Biomarker for successful aging without cognitive decline
WO2014116666A1 (en) Methods and kits for treating and classifying individuals at risk of or suffering from a neurological dysfunction or disorder
WO2008052115A1 (en) Materials and methods for predicting physiological responses to cardiovascular drugs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210428

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210525

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210927